On June 11, 2026, stockholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5,000,000 to 9,000,000 and extending the plan term to January 31, 2030. The amendment prohibits the repricing, replacing, or cash-out of stock options or SARs without stockholder approval and reduces maximum annual compensation limits for non-employee directors and individual equity awards. Other annual meeting results included the election of directors Richard J. Barry, Pierre Gravier, and Claude Nicaise, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026. Filana Therapeutics, Inc. is a biotechnology company that develops therapeutic treatments.